Placebo Effect Raises Questions About Clinical Value For Depomed, Noven Hot Flash Treatments
Executive Summary
Advisory Committee for Reproductive Health Drugs asks whether FDA standards are too difficult to meet for non-hormonal products like gabapentin and paroxetine after the placebo arms of both drugs’ trials show a strong reduction in vasomotor symptoms.
You may also be interested in...
FDA Ties Brisdelle Approval To Unmet Need For Hormone-Free Therapy
In an NEJM perspective piece, agency reviewers explain why they believed Noven’s paroxetine for treating hot flashes should come to market despite only “modest” efficacy and an advisory committee’s overwhelming recommendation against approval.
Depomed Hot Flash Drug May Finally Be On Its Way To FDA
Despite the product’s rocky history, Depomed says it is ready to file its non-hormonal hot flash treatment Serada (extended-release gabapentin) based on a recent meeting with FDA. But a mixed Phase III dataset raises doubts about approvability.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.